RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 11.58

Change

+0.15 (+1.31)%

Market Cap

N/A

Volume

5.30K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-10 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

+0.66 (+1.56%)

USD 0.89B
SOXS Direxion Daily Semiconductor B..

+1.49 (+7.46%)

USD 0.73B
PSQ ProShares Short QQQ

+0.61 (+1.64%)

USD 0.51B
SPXU ProShares UltraPro Short S&P50..

+1.02 (+4.59%)

USD 0.50B
SDOW ProShares UltraPro Short Dow30

+2.49 (+4.93%)

USD 0.26B
YANG Direxion Daily FTSE China Bear..

+6.40 (+8.34%)

USD 0.16B
SPDN Direxion Daily S&P 500® Bear ..

+0.18 (+1.64%)

USD 0.14B
RWM ProShares Short Russell2000

+0.42 (+2.25%)

USD 0.14B
DOG ProShares Short Dow30

+0.45 (+1.70%)

USD 0.13B
DUST Direxion Daily Gold Miners Ind..

+0.13 (+0.21%)

USD 0.11B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.69% 15% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.69% 15% F 23% F
Trailing 12 Months  
Capital Gain 2.75% 98% N/A 50% F
Dividend Return 3.70% 74% C 53% F
Total Return 6.45% 98% N/A 48% F
Trailing 5 Years  
Capital Gain -65.44% 69% C- 6% D-
Dividend Return 2.71% 64% D 7% C-
Total Return -62.73% 69% C- 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 62.77% 40% F 95% A
Dividend Return 63.96% 40% F 95% A
Total Return 1.19% 57% F 29% F
Risk Return Profile  
Volatility (Standard Deviation) 433.86% 62% D 3% F
Risk Adjusted Return 14.74% 45% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.